Literature DB >> 25035302

Acyl transfer mechanisms of tissue transglutaminase.

Jeffrey W Keillor1, Christopher M Clouthier2, Kim Y P Apperley2, Abdullah Akbar2, Amina Mulani2.   

Abstract

Tissue transglutaminase (TG2) is a calcium-dependent enzyme that catalyses several acyl transfer reactions. The most biologically relevant of these involve protein-bound Gln residues as an acyl-donor substrate, and either water or a primary amine as an acyl-acceptor substrate. The former leads to deamidation of Gln to Glu, whereas the latter leads to transamidation, typically resulting in protein cross-linking when the amine substrate is a protein-bound Lys residue. In this review, we present an overview of over fifty years of mechanistic studies that have led to our current understanding of TG2-mediated hydrolysis and transamidation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acyl transfer; Enzyme mechanism; Transamidation; Transglutaminase

Mesh:

Substances:

Year:  2014        PMID: 25035302     DOI: 10.1016/j.bioorg.2014.06.003

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  22 in total

Review 1.  Chemoenzymatic Semisynthesis of Proteins.

Authors:  Robert E Thompson; Tom W Muir
Journal:  Chem Rev       Date:  2019-11-27       Impact factor: 60.622

Review 2.  Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Eur J Med Chem       Date:  2020-05-18       Impact factor: 6.514

3.  Proteolytic and nonproteolytic activation mechanisms result in conformationally and functionally different forms of coagulation factor XIII A.

Authors:  Boris A Anokhin; William L Dean; Kerrie A Smith; Matthew J Flick; Robert A S Ariëns; Helen Philippou; Muriel C Maurer
Journal:  FEBS J       Date:  2019-08-28       Impact factor: 5.542

4.  Sulforaphane covalently interacts with the transglutaminase 2 cancer maintenance protein to alter its structure and suppress its activity.

Authors:  Ellen A Rorke; Gautam Adhikary; Henryk Szmacinski; Joseph R Lakowicz; David J Weber; Raquel Godoy-Ruiz; Purushottamachar Puranik; Jeffrey W Keillor; Eric W J Gates; Richard L Eckert
Journal:  Mol Carcinog       Date:  2021-10-05       Impact factor: 4.784

5.  Structure-activity relationships of hydrophobic alkyl acrylamides as tissue transglutaminase inhibitors.

Authors:  Alana M M Rangaswamy; Pauline Navals; Eric W J Gates; Sammir Shad; Sarah K I Watt; Jeffrey W Keillor
Journal:  RSC Med Chem       Date:  2022-01-26

6.  Ethacrynic acid is an inhibitor of human factor XIIIa.

Authors:  Srabani Kar; Kayla Vu; Madhusoodanan Mottamal; Rami A Al-Horani
Journal:  BMC Pharmacol Toxicol       Date:  2022-06-01       Impact factor: 2.605

7.  Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.

Authors:  Abdullah Akbar; Nicole M R McNeil; Marie R Albert; Viviane Ta; Gautam Adhikary; Karine Bourgeois; Richard L Eckert; Jeffrey W Keillor
Journal:  J Med Chem       Date:  2017-09-14       Impact factor: 7.446

8.  Development of new scaffolds as reversible tissue transglutaminase inhibitors, with improved potency or resistance to glutathione addition.

Authors:  Kim Y P Apperley; Isabelle Roy; Vincent Saucier; Nicholas Brunet-Filion; Sara-Pier Piscopo; Christophe Pardin; Élise De Francesco; Catherine Hao; Jeffrey W Keillor
Journal:  Medchemcomm       Date:  2016-12-05       Impact factor: 3.597

9.  Vasohibins: new transglutaminase-like cysteine proteases possessing a non-canonical Cys-His-Ser catalytic triad.

Authors:  Luis Sanchez-Pulido; Chris P Ponting
Journal:  Bioinformatics       Date:  2016-01-21       Impact factor: 6.937

10.  Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.

Authors:  C Kerr; H Szmacinski; M L Fisher; B Nance; J R Lakowicz; A Akbar; J W Keillor; T Lok Wong; R Godoy-Ruiz; E A Toth; D J Weber; R L Eckert
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.